Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplishment, American, arm, ASCO, conference, confirming, doubling, ductal, Fast, fiscal, Gastrointestinal, injection, irinotecan, liposomal, liposome, mPDAC, NALIRIFOX, NAPOLI, objective, oxaliplatin, pausing, PFS, proceed, regimen, RESILIENT, serbantumab, small, Society, statistically, Symposium, tied, topotecan, unclear, untreated, upcoming
Filing tables
Filing exhibits
MACK similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement of Merrimack Pharmaceuticals, Inc. on Form S-3 (No. 333-222093) and Form S-8 (Nos. 333-180996, 333-186370, 333-194313, 333-202346, 333-209745, 333-223577, 333-230084, 333-237155 and 333- 268609) of our report dated March 9, 2023 with respect to our audits of the consolidated financial statements of Merrimack Pharmaceuticals, Inc. as of December 31, 2022 and 2021 and for the years then ended, which report is included in this Annual Report on Form 10-K of Merrimack Pharmaceuticals, Inc. for the year ended December 31, 2022.
/s/ Marcum LLP
Marcum LLP
Boston, Massachusetts
March 9, 2023